Hormonal
Decreases in FGF-21 levels during weight loss maintenance are associated with improvements in hepatic insulin sensitivity, suggesting a resolution of FGF-21 resistance.
Improving your liver's sensitivity to insulin is a key goal of weight loss. This study suggests that as your FGF-21 levels drop (which happens with weight loss, especially low-carb diets), your liver becomes more responsive to insulin. This is a positive metabolic adaptation.
Change in FGF-21 was inversely associated with change in hepatic IS [Beta = −0.565 units/log(ng/mL), P = 0.02]... These findings may elucidate relationships between dietary composition, insulin sensitivity and metabolism.
Why this rating
Statistically significant association (P=0.02) in a controlled crossover trial, though causality is inferred.
Source
Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism
Bridget M. Hron et al. · Nutrition & Metabolism · 2017
DOI 10.1186/s12986-017-0198-y
More from this paper
- Dietary interventions that induce weight loss decrease circulating FGF-21 levels, with the magnitude of decrease being inversely proportional to carbohydrate content (very low carbohydrate diets causing the greatest reduction).Good
- Dietary intervention (weight loss maintenance) increases fasting ghrelin levels and decreases chemerin levels, independent of macronutrient composition.Good
- Dietary intervention (weight loss maintenance) increases circulating Heme-oxygenase-1 (HO-1) levels, with a non-significant trend toward greater increases on Low Glycemic Index diets.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →